CD5 CAR-T therapy for returning blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a CD5-positive B-cell lymphoma (like CLL, mantle cell, or diffuse large B-cell lymphoma) that is relapsed or refractory after prior therapies.
- Or you must have a CD5-positive T-cell lymphoma (like peripheral T-cell lymphoma) that is relapsed or refractory after at least one prior treatment.
- You are between 18 and 70 years old.
- You have at least one measurable tumor (≥1.5 cm) or bone marrow involvement.
- Your liver, kidney, and heart function must be within acceptable ranges, and you must have a good performance status (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Hear when a new Relapsed and Refractory CD5 Hematological Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.